India and Taiwan have formed a new partnership to develop and promote breakthrough health-tech solutions. The International Trade Administration, Government of Taiwan, and the Commerce Development Research Institute (CDRI), as the Taiwan...
Deuruxolitinib is an experimental medication for the treatment of moderate to severe alopecia areata, and Sun Pharmaceutical Industries Ltd. has reported that the United States Food and Drug Administration (USFDA) has approved its new drug...
Sai Life Sciences, the fastest-growing contract research, development, and manufacturing company in India, has chosen Dassault Systèmes' solutions to boost productivity, improve data quality, and promote collaboration in its research and...
Transcenta Holding Limited, a clinical stage biopharmaceutical company, announces that the FDA has approved the TranStar 301 global phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line...
For many years, the discipline of drug formulation has been a pillar of the pharmaceutical business.
The US Food and Drug Administration (FDA) has released new draft recommendations to help sponsors develop therapies for stimulant use disorders. When it is completed, the guidance, Stimulant Use Disorders: Developing Drugs for Treatment, will be...
Sanofi and Teva Pharmaceuticals, a US division of Teva Pharmaceutical Industries Ltd., announce a partnership to co-develop and co-commercialize TEV'574, an inflammatory bowel disease treatment drug currently undergoing phase 2b clinical trials...
Amber Implants, a cutting-edge medical technology firm producing next-generation spinal implants, has announced the formal commencement of clinical trials for the VCFix Spinal System. This first-in-human clinical trial will evaluate the safety and...
Alembic Pharmaceuticals Limited stated that six of its abbreviated new drug applications (ANDA) were approved by the US Food and Drug Administration (US FDA) during Q2FY24. The company has received six...
Sanofi has announced a deal with Janssen Pharmaceuticals, Inc, a Johnson & Johnson business, to develop and commercialize Janssen's vaccine candidate for extraintestinal pathogenic E. coli (9-valent), which is now in phase 3. The deal combines...
, CDSCO.jpg)
.jpg)